Annals of Oncology 13:1205-1211, 2002
© 2002 European Society for Medical Oncology
Original Paper |
Increased cyclooxygenase-2 (COX-2) expression is associated with chemotherapy resistance and outcome in ovarian cancer patients
Department of 1 Obstetrics and Gynecology, 2 Pathology and 3 Histology, Catholic University of the Sacred Heart, Rome, Italy
Received 9 November 2001; revised 8 February 2002; accepted 8 March 2002
Background:
Cyclooxygenase-2 (COX-2) expression is associated with aggressive clinicopathological parameters and unfavourable prognosis in several human malignancies. The aim of this study was to investigate the expression of COX-2 and its association with clinicopathological parameters, response to treatment, and clinical outcome in ovarian cancer patients.
Patients and methods:
COX-2 expression was analysed by immunohistochemistry in 87 primary ovarian carcinomas from patients with measurable disease after primary laparotomy.
Results:
COX-2 immunoreaction was observed in 39 (44.8%) cases, and did not differ in distribution according to age, FIGO stage, debulking at time of surgery, presence of ascites, histotype or tumour grade. Both in patients cytoreduced at first surgery and in those undergoing only explorative laparotomy, the percentage of COX-2 positivity was significantly higher in non-responding than in patients responding to treatment (P = 0.043 and P = 0.0018, respectively). In multivariate analysis, only COX-2 positivity and older age retained an independent role in predicting a poor chance of response to treatment. There was no significant difference of clinical outcome according to COX-2 status in patients undergoing primary debulking while, in the subgroup of patients who underwent explorative laparotomy, COX-2-positive cases showed a shorter time to progression (P = 0.025) and overall survival (P = 0.025).
Conclusions:
The assessment of COX-2 status could provide additional information in order to identify ovarian cancer patients with a poor chance of response to chemotherapy and potentially candidates for more individualised treatments.
Key words: chemotherapy response, COX-2, ovarian cancer, prognosis
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. THILL, D. FISCHER, S. BECKER, T. CORDES, C. DITTMER, K. DIEDRICH, D. SALEHIN, and M. FRIEDRICH Prostaglandin Metabolizing Enzymes in Correlation with Vitamin D Receptor in Benign and Malignant Breast Cell Lines Anticancer Res, September 1, 2009; 29(9): 3619 - 3625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. R. Holla, M. G. Backlund, P. Yang, R. A. Newman, and R. N. DuBois Regulation of Prostaglandin Transporters in Colorectal Neoplasia Cancer Prevention Research, July 1, 2008; 1(2): 93 - 99. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Stadlmann, U. Gueth, E. Wight, L. A Kunz-Schughart, A. Hartmann, and G. Singer Expression of peroxisome proliferator activated receptor {gamma} and cyclo-oxygenase 2 in primary and recurrent ovarian carcinoma J. Clin. Pathol., March 1, 2007; 60(3): 307 - 310. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ferrandina, F. O. Ranelletti, F. Legge, V. Salutari, E. Martinelli, A. Fattorossi, D. Lorusso, G. Zannoni, V. Vellone, A. Paglia, et al. Celecoxib Up-Regulates the Expression of the {zeta} Chain of T Cell Receptor Complex in Tumor-Infiltrating Lymphocytes in Human Cervical Cancer. Clin. Cancer Res., April 1, 2006; 12(7): 2055 - 2060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Bagnato, F. Spinella, and L. Rosano Emerging role of the endothelin axis in ovarian tumor progression Endocr. Relat. Cancer, December 1, 2005; 12(4): 761 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Fanfani, A. Fagotti, G. Ferrandina, G. Bifulco, F. Legge, D. Lorusso, L. Minelli, and G. Scambia Increased cyclooxygenase-2 expression is associated with better clinical outcome in patients submitted to complete ablation for severe endometriosis Hum. Reprod., October 1, 2005; 20(10): 2964 - 2968. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Symowicz, B. P. Adley, M. M.M. Woo, N. Auersperg, L. G. Hudson, and M. S. Stack Cyclooxygenase-2 Functions as a Downstream Mediator of Lysophosphatidic Acid to Promote Aggressive Behavior in Ovarian Carcinoma Cells Cancer Res., March 15, 2005; 65(6): 2234 - 2242. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Kerr A word in your ear: the 2004 Annals of Oncology prizes Ann. Onc., September 1, 2004; 15(9): 1303 - 1304. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Sirois, K. Sayasith, K. A. Brown, A. E. Stock, N. Bouchard, and M. Dore Cyclooxygenase-2 and its role in ovulation: a 2004 account Hum. Reprod. Update, September 1, 2004; 10(5): 373 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Spaner Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Spinella, L. Rosano, V. Di Castro, M. R. Nicotra, P. G. Natali, and A. Bagnato Inhibition of Cyclooxygenase-1 and -2 Expression by Targeting the Endothelin A Receptor in Human Ovarian Carcinoma Cells Clin. Cancer Res., July 15, 2004; 10(14): 4670 - 4679. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Kulke, R. D. Odze, J. D. Mueller, H. Wang, M. Redston, and M. M. Bertagnolli Prognostic significance of vascular endothelial growth factor and cyclooxygenase 2 expression in patients receiving preoperative chemoradiation for esophageal cancer J. Thorac. Cardiovasc. Surg., June 1, 2004; 127(6): 1579 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferrandina, F. O. Ranelletti, F. Legge, M. Gessi, V. Salutari, M. G. Distefano, L. Lauriola, G. F. Zannoni, E. Martinelli, and G. Scambia Prognostic Role of the Ratio between Cyclooxygenase-2 in Tumor and Stroma Compartments in Cervical Cancer Clin. Cancer Res., May 1, 2004; 10(9): 3117 - 3123. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Fagotti, G. Ferrandina, F. Fanfani, F. Legge, L. Lauriola, M. Gessi, P. Castelli, F. Barbieri, L. Minelli, and G. Scambia Analysis of cyclooxygenase-2 (COX-2) expression in different sites of endometriosis and correlation with clinico-pathological parameters Hum. Reprod., February 1, 2004; 19(2): 393 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-L. Erkinheimo, H. Lassus, P. Finne, B. P. van Rees, A. Leminen, O. Ylikorkala, C. Haglund, R. Butzow, and A. Ristimaki Elevated Cyclooxygenase-2 Expression Is Associated with Altered Expression of p53 and SMAD4, Amplification of HER-2/neu, and Poor Outcome in Serous Ovarian Carcinoma Clin. Cancer Res., January 15, 2004; 10(2): 538 - 545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ferrandina, F. O. Ranelletti, F. Legge, L. Lauriola, V. Salutari, M. Gessi, A. C. Testa, U. Werner, P. Navarra, G. Tringali, et al. Celecoxib Modulates the Expression of Cyclooxygenase-2, Ki67, Apoptosis-Related Marker, and Microvessel Density in Human Cervical Cancer: A Pilot Study Clin. Cancer Res., October 1, 2003; 9(12): 4324 - 4331. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Agarwal, C. Denkert, and S. Hauptmann The Function of COX-2 in Human Ovarian Carcinoma Am. J. Pathol., July 1, 2003; 163(1): 368 - 369. [Full Text] [PDF]
|
|